KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.

Francois Guilhot, Françoise Rigal-Huguet, Joëlle Guilhot, Agnès-Paule Guerci-Bresler, Frédéric Maloisel, Delphine Rea, Valérie Coiteux, Martine Gardembas, Christian Berthou, Anne Vekhoff, Eric Jourdan, Marc Berger, Loïc Fouillard, Magda Alexis, Laurence Legros, Philippe Rousselot, Alain Delmer, Pascal Lenain, Martine Escoffre Barbe, Emmanuel Gyan, Claude-Eric Bulabois, Viviane Dubruille, Bertrand Joly, Bertrand Pollet, Pascale Cony-Makhoul, Hyacinthe Johnson-Ansah, Melanie Mercier, Denis Caillot, Aude Charbonnier, Jean-Jacques Kiladjian, Jacques Chapiro, Amélie Penot, Véronique Dorvaux, Iona Vaida, Alberto Santagostino, Lydia Roy, Hacene Zerazhi, Eric Deconinck, Herve Maisonneuve, Isabelle Plantier, Delphine Lebon, Yazid Arkam, Nathalie Cambier, Kamel Ghomari, Jean-Michel Miclea, Sylvie Glaisner, Jean-Michel Cayuela, Jean-Claude Chomel, Marc Muller, Ludovic Lhermitte, Marc Delord, Claude Preudhomme, Gabriel Etienne, François-Xavier Mahon, Franck-Emmanuel Nicolini, France Intergroupe des Leucémies Myéloïdes Chroniques, Fi-LMC

Leukemia 35(8) 2332-2345

PMID33483613
PMCID-
DOI10.1038/s41375-020-01117-w
发表日期2021-01-23
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

The STI571 prospective randomised trial (SPIRIT) French trial is a four-arm study comparing imatinib (IM) 400 mg versus IM 600 mg, IM 400 mg + cytarabine (AraC), and IM 400 mg + pegylated interferon alpha2a (PegIFN-α2a) for the front-line treatment of chronic-phase chronic myeloid leukaemia (CML). Long-term analyses included overall and progression-free survival, molecular responses to treatment, and severe adverse events. Starting in 2003, the trial included 787 evaluable patients. The median overall follow-up of the patients was 13.5 years (range 3 months to 16.7 years). Based on intention-to-treat analyses, at 15 years, overall and progression-free survival were similar across arms: 85%, 83%, 80%, and 82% and 84%, 87%, 79%, and 79% for the IM 400 mg (N = 223), IM 600 mg (N = 171), IM 400 mg + AraC (N = 172), and IM 400 mg + PegIFN-α2a (N = 221) arms, respectively. The rate of major molecular response at 12 months and deep molecular response (MR4) over time were significantly higher with the combination IM 400 mg + PegIFN-α2a than with IM 400 mg: p = 0.0001 and p = 0.0035, respectively. Progression to advanced phases and secondary malignancies were the most frequent causes of death. Toxicity was the main reason for stopping AraC or PegIFN-α2a treatment.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。